-transparent.png){kind=logo}
A preparative purification of endogenous inhibitors of the Na+/K+-ATPase has been carried out from bovine blood. Dried plasma was deproteinized, hexane-extracted and desalted, followed by further purification through a series of reverse-phase HPLC fractionations. Fractions active in inhibiting Na+/K+-ATPase activity and displacing ouabain were collected and purified further. By comparison with ouabain, the final extract was found to have a steeper concentration-effect curve in the inhibition of Na+/K+-ATPase. In displacement of [3H]ouabain, the extract had again a steeper concentration-effect curve than does ouabain, and in addition it enhanced ouabain binding at high dilutions. These properties are indicative of nonspecific interactions with the Na+/K+-ATPase. The active fraction was identified by TLC, HPLC, NMR, GLC and GC-MS, to be a mixture of three unesterified fatty acids, mainly oleic acid (72% of the total) and three saturated hydrocarbons. The assignment of structures was corroborated by comparison with authentic samples.
D M Tal, and
M D Yanuck, and
G van Hall, and
S J Karlish
August 1985,
The Journal of biological chemistry,
D M Tal, and
M D Yanuck, and
G van Hall, and
S J Karlish
November 1987,
Hypertension (Dallas, Tex. : 1979),
D M Tal, and
M D Yanuck, and
G van Hall, and
S J Karlish
September 1986,
The Journal of biological chemistry,
D M Tal, and
M D Yanuck, and
G van Hall, and
S J Karlish
January 1998,
Clinical and experimental hypertension (New York, N.Y. : 1993),
D M Tal, and
M D Yanuck, and
G van Hall, and
S J Karlish
May 1987,
Biochemistry,
D M Tal, and
M D Yanuck, and
G van Hall, and
S J Karlish
September 1993,
General pharmacology,
D M Tal, and
M D Yanuck, and
G van Hall, and
S J Karlish
June 2010,
Molecular pharmacology,
D M Tal, and
M D Yanuck, and
G van Hall, and
S J Karlish
April 1977,
Journal of molecular and cellular cardiology,
D M Tal, and
M D Yanuck, and
G van Hall, and
S J Karlish
January 1988,
Progress in clinical and biological research,
D M Tal, and
M D Yanuck, and
G van Hall, and
S J Karlish
January 2014,
Current drug targets,
